Microfluidics Formulated Liposomes of Hypoxia Activated Prodrug for Treatment of Pancreatic Cancer
- Supplementary File 1:
ZIP-Document (ZIP, 383 KiB)
Shah, V.M.; Dorrell, C.; Al-Fatease, A.; Allen-Petersen, B.L.; Woo, Y.; Bortnyak, Y.; Gheewala, R.; Sheppard, B.C.; Sears, R.C.; Alani, A.W. Microfluidics Formulated Liposomes of Hypoxia Activated Prodrug for Treatment of Pancreatic Cancer. Pharmaceutics 2022, 14, 713. https://doi.org/10.3390/pharmaceutics14040713
Shah VM, Dorrell C, Al-Fatease A, Allen-Petersen BL, Woo Y, Bortnyak Y, Gheewala R, Sheppard BC, Sears RC, Alani AW. Microfluidics Formulated Liposomes of Hypoxia Activated Prodrug for Treatment of Pancreatic Cancer. Pharmaceutics. 2022; 14(4):713. https://doi.org/10.3390/pharmaceutics14040713
Chicago/Turabian StyleShah, Vidhi M., Craig Dorrell, Adel Al-Fatease, Brittany L. Allen-Petersen, Yeonhee Woo, Yuliya Bortnyak, Rohi Gheewala, Brett C. Sheppard, Rosalie C. Sears, and Adam WG. Alani. 2022. "Microfluidics Formulated Liposomes of Hypoxia Activated Prodrug for Treatment of Pancreatic Cancer" Pharmaceutics 14, no. 4: 713. https://doi.org/10.3390/pharmaceutics14040713